


2 DOSES. 1 MONTH.<sup>1</sup>

**HEPLISAV-B**<sup>®</sup>  
Hepatitis B Vaccine (Recombinant), Adjuvanted

**ORDER TODAY**

## HEPLISAV-B Provides Faster Protection With 2-Dose Completion in 1 Month<sup>1</sup>

Series completion is critical to help ensure protective immunity<sup>2</sup>



In the era of **universal adult hepatitis B vaccination...**<sup>3</sup>



Fewer shots for your patients,  
staff, and office  
(as compared to other hepatitis B vaccines)<sup>3-5</sup>

**LEARN MORE** ▶

Refer to page 2 for important billing and coding information.

### INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

### IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see additional Important Safety Information throughout and scan the QR code on page 2 for full [Prescribing Information](#).

2 DOSES. 1 MONTH.!

**HEPLISAV-B**<sup>®</sup>  
Hepatitis B Vaccine (Recombinant), Adjuvanted

# BILLING AND CODING INFORMATION

The table below lists relevant codes to help facilitate reimbursement of HEPLISAV-B administration. The information is for reference only and does not guarantee code appropriateness or reimbursement.

Type	Code	Description
CPT <sup>®</sup> Drug Code <sup>6</sup>	90739	Hepatitis B vaccine, adult dosage 2-dose schedule, for intramuscular use
CPT Administration Code <sup>6</sup>	90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
HCPCS (Administration code for Medicare Part B) <sup>7</sup>	G0010	Administration of hepatitis B vaccine
10-Digit NDC Number <sup>1</sup>	43528-003-01 43528-003-01	Prefilled syringe, 1 dose (0.5 mL) Package of 5 single-dose prefilled syringes
11-Digit NDC Number <sup>1</sup>	43528-0003-01 43528-0003-05	Prefilled syringe, 1 dose (0.5 mL) Package of 5 single-dose prefilled syringes
ICD-10-CM <sup>8</sup>	Z23	Encounter for immunization
MVX Code <sup>9</sup>	DVX	Dynavax
CVX Code <sup>10</sup>	189	Hepatitis B vaccine (recombinant), adjuvant

**Commercial insurance, Medicare, and Medicaid must cover ACIP-recommended vaccines, like HEPLISAV-B, with no cost-sharing<sup>11-13</sup>**

## IMPORTANT SAFETY INFORMATION (CONT.)

There are no clinical studies of HEPLISAV-B in pregnant women. Available human data on HEPLISAV-B administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

It is not known whether HEPLISAV-B is excreted in human milk. Data are not available to assess the effects of HEPLISAV-B on the breastfed infant or on milk production/excretion.

Vaccination with HEPLISAV-B may not result in protection of all vaccine recipients.

To report suspected adverse reactions, contact **1-84-HEPLISAV (1-844-375-4728)** or the **FDA at 1-800-FDA-1088** or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).



Please scan or click the QR code or ask your representative for full [Prescribing Information](#).

ACIP, Advisory Committee on Immunization Practices; CPT, Current Procedural Terminology; CVX, vaccine administered; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; MVX, Manufacturer of Vaccine; NDC, National Drug Code.

**REFERENCES:** 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2023. 2. Centers for Disease Control and Prevention. Hepatitis B basics. Accessed May 21, 2024. <https://www.cdc.gov/hepatitis-b/about> 3. Centers for Disease Control and Prevention. Immunization schedules: Table 1. Recommended adult immunization schedule for ages 19 or older, United States, 2024. Accessed January 26, 2024. <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html#table-age> 4. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. *JAMA Netw Open*. 2020;3(11):e2027577. 5. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. *Am J Public Health*. 2009;99(Suppl 2):S389-S397. 6. American Medical Association. 2024 CPT Professional Edition. Current Procedural Terminology (CPT<sup>®</sup>) Copyright 2024 American Medical Association. All rights reserved. CPT<sup>®</sup> is a registered trademark of the American Medical Association. Chicago, IL: AMA; 2024. 7. Codify by AAPC. HCPCS Code for administration of hepatitis B vaccine G0010. Accessed May 1, 2024. <https://www.aapc.com/codes/hcpcs-codes/G0010> 8. ICD10Data.com. 2024 ICD-10-CM diagnosis code Z23. Accessed May 1, 2024. <https://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z29/Z23-Z23> 9. Centers for Disease Control and Prevention. Immunization information system (IIS): HL7 standard code set MVX - manufacturers of vaccines. Accessed May 1, 2024. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mvx> 10. Centers for Disease Control and Prevention. Immunization information system (IIS): HL7 standard code set CVX - vaccines administered. Accessed May 1, 2024. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx> 11. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(13):477-483. 12. Affordable Care Act. Public law section 300gg-13. Accessed May 23, 2024. <https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf> 13. Inflation Reduction Act. Public law section 11401. Accessed May 23, 2024. <https://www.congress.gov/117/plaws/publ169/PLAW-117publ169.pdf>

**DYNAVAX**

DYNAVAX and HEPLISAV-B are registered trademarks of Dynavax Technologies Corporation. CPT is a registered trademark of the American Medical Association (AMA). © 2024 Dynavax. All rights reserved. US-24-00-00097 | July 2024